Enrollment closed • Phase classification • Trial completion date • Trial primary completion date
|
MET (MET proto-oncogene, receptor tyrosine kinase)
|
EGFR mutation • EGFR T790M • MET exon 14 mutation • IDH wild-type
|
Tagrisso (osimertinib) • Tepmetko (tepotinib)